Corrigendum to "Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor" [Biochem. Biophys. Rep. 21 (2020) 100726]

Biochem Biophys Rep. 2020 Aug 20:24:100797. doi: 10.1016/j.bbrep.2020.100797. eCollection 2020 Dec.

¹ Innovation Promotion, Shonan Research Central Office, Research, Takeda Pharmaceutical Company Limited, 2-26-1 Muraoka-Higashi, Fujisawa-shi, Kanagawa, 251-8555, Japan.
² Oncology Therapeutic Area Unit for Japan & Asia, Takeda Pharmaceutical Company Limited, 4-1-1 Dosho-machi Chuo-ku Osaka-shi, Osaka, 540-8645, Japan.
³ Department of Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, 2-1-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8668, Japan.
⁴ Axcelead Drug Discovery Partners, Inc., 2-26-1Muraoka-Higashi, Fujisawa-shi, Kanagawa, 251-0012, Japan.

Abstract

[This corrects the article DOI: 10.1016/j.bbrep.2020.100726.].